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Introduction
H
epatitis B virus (HBV) has affected more 
than  2  billion  people  worldwide  (about 
one third of the world’s population) with more than 
350  million  people  chronically  infected.  Chronic 
hepatitis B is a dangerous disease that can lead to 
liver  cirrhosis  and  subsequently  to  hepatocellular 
carcinoma (HCC) (1). 
HBV is a double-stranded DNA virus belonging to 
the hepadnavirus family replicating an intermediate 
RNA,  the  pregenomic  RNA  (pgRNA);  this  very 
much  resembles  the  mechanism  of  HIV  virus 
replication (1, 2). 
Hydroxyurea  (HU)  is  a  drug  with  a  history 
of  more  than  40  years  use  in  the  treatment  of 
hematological malignancies such as chronic myeloid 
leukemia (CML) and diseases like sickle cell anemia, 
polycythemia  vera,  and  psoriasis.  HU  is  a  free 
radical quencher, and inhibits the cellular enzyme 
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Background and Aims: To introduce the possible role of hydroxyurea (HU), a well-characterized antineoplastic drug with 
established antiviral effects, in the treatment of chronic hepatitis B.
Methods: Four antiretroviral-naïve patients with chronic hepatitis B were enrolled in this limited pilot trial, and given 
1000 mg/day of hydroxyurea for 4 weeks; then, the administration of the drug was suspended for 4 weeks. A clinical 
study and laboratory safety assessments and measurements of viral load were made at baseline, after drug therapy, and 
after one month suspension of the treatment.
Results: All 4 patients showed a significant decrease in viral load after 4 weeks of hydroxyurea therapy and the viral load 
of 2 patients increased again after a 4-week suspension of hydroxyurea. 
Conclusions: Our data demonstrate that the old low-cost antineoplastic drug, hydroxyurea, efficiently blocks hepatitis B 
virus (HBV) replication. We suggest that HU will play an important role in the treatment of chronic hepatitis in the fore-
seeable future. Further studies including those that evaluate optimal dosing in long-term use will continue to define the 
role of HU in the treatment of HBV infection alone or in combination with other antiviral drugs.
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ribonuclotide  reductase,  the  rate  limiting  enzyme 
responsible  for  the  conversion  of  ribonucleotides 
to  deoxyribonucleotides,  which  is  essential  for 
DNA synthesis  (3). This amazing biological effect 
has stimulated interest in HU for the treatment of 
diseases which are mediated by DNA viruses such 
as  human  immunodeficiency  virus  (HIV),  herpes 
simplex virus (HSV) and polyomavirus (4-6). 
This  astonishing  characteristic  of  HU  has 
marked  the  last  decade  for  its  initiation  of  the 
application of HU to AIDS therapy, for the first 
time in history (7). 
Since  there  is  abundant  evidence  for  the 
positive  effects  of  HU  in  decreasing  HIV  and 
HSV replication, and because of the similarity of 
the HIV and HBV replication processes, we have 
postulated HU’s possible effect in decreasing HBV 
replication.
 
Materials and Methods
To explore whether HU could be used to decrease 
HBV  viral  load,  we  conducted  a  limited  trial  on 
patients with chronic hepatitis B.
The  four  patients  whose  chronic  hepatitis  B 
positivity was definite were male with an age range of 
29-58. They had not received any kind of treatment 
before they participated in our research. None of 
them had any sign of being previously or presently 
affected  by  hepatitis  A,  C,  D,  and  HIV.  Liver 
biopsy also indicated their active chronic hepatitis 
with HBV. Other routine tests including complete 
blood count (CBC), albumin and prothrombin time 
showed completely normal results. 
All patients were fully informed of the effects of 
the drug and instructed in its use. Afterwards, they 
gave their informed consent so as to be allowed to 
participate in the study. For four weeks on a daily 
basis, the patients received 1000 mg HU medication. 
During this four-week therapy period, the patients 
were examined once a week for any possible side 
effects  and  underwent  a  CBC  test.  We  evaluated 
the HBV replication rate by estimating HBV viral 
load before and after the first month of treatment 
with HU, by means of the polymerase chain reaction 
(PCR), similar to the method followed in previous 
studies (8). In order to confirm the results, all patients 
were retested for HBV viral load one month after the 
end of the treatment. 
The levels of viral load prior to the study were more 
than 106 copies/mL. Each patient was given this test 
three times: prior to the treatment, at the end of drug 
therapy, and one month after the end of therapy.
Results
Finally, after two months, none of the patients 
showed any side effects; on the contrary, wonderful 
effects of the drug were revealed. Complete viral load 
results during the study appear in Table 1 and Fig 1. 
Discussion
As mentioned before, the most important goal in 
the treatment of chronic hepatitis B is to reduce HBV 
load; and HU was shown to be capable of putting this 
into practice. Moreover, a recurring increase in HBV 
in half of the patients (two out of four) after a month 
of  drug  suspension  strengthens  our  conclusions. 
Finally, given the HBV load of zero in one of the 
patients, the hypothesis of the HU effect in hepatitis 
B treatment is further confirmed. 
The  findings  of  the  present  study  are  to  be 
considered as the primary basis upon which further 
comprehensive  and  more  detailed  studies  are 
recommended for the evaluation of the impact of 
HU as a possible drug effective in the treatment of 
hepatitis B. HU is simply absorbed orally and any 
probable or rare side effects, in case of occurrence, can 
be prevented by discontinuation of the drug (3, 7). 
It  is  worth  mentioning  that  any  claim  that  a 
certain  drug  is  capable  of  fully  hindering  HBV 
replication should be accompanied by its practical 
effect on the reduction of initial viral load by more 
than 2 logs (8); this happened in the case of just 
one of our patients. Furthermore, the very short 
HU  treatment  time  span  of  the  present  study 
should  not  be  overlooked.  While  most  of  the 
drugs administered to target hepatitis B take four 
months for their effects to appear, HU manifested 
its wonderful effectiveness after less than a month. 
Therefore, we anticipate even greater effects of HU 
in  suppressing  HBV  replication,  the  longer  the 
duration of treatment. 
Table 1. Dynamic parameters related to HBV viral 
load (copies/mL) of patients.
1st  2nd  3rd  4th
patients  patient  patient  patient
Baseline  95.55*106 4.47*106 5.89*106 2.62*106
After drug
treatment  21.32*106 0.63*106 2.49*106 0.0
After drug
suspension  314*106 0.67*106 6.84*106 0.02*106Hepatitis Monthly, Summer 2010; 10(3): 215-217
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Altogether, there are reasons to support the claim 
that HU is a very excellent drug for the treatment of 
hepatitis B: 
HU has been a well-recognized drug throughout  1. 
its years of use. 
It is simply absorbed orally and is easily absorbed  2. 
into all bodily fluids. 
Toxicity of this drug is very low and in case of  3. 
any  side  effects  mere  discontinuation  can  end 
complications. 
The most important reason for drug resistance  4. 
is  mutation.  HU,  by  causing  a  reduction  in 
the production and replication of HBV in fact 
lowers the chance of mutations, thereby reducing 
resistance. 
In  any  case,  it  seems  that  further  and  more 
comprehensive  studies  of  HU  in  isolation  or  in 
combination with other drugs can be very helpful in 
shedding light on all relevant aspects.
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Figure 1. Kinetics of HBV during study (logarithmic).
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